Non-vision adverse events with vigabatrin therapy

Acta Neurologica Scandinavica

Volumn 124, Issue SUPPL. 192, 2011, Pages 72-82

  Walker, S D ^a   Kalviainen R ^b  

^a Fleishman Hillard Inc   (United States)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adverse events; Complex partial seizures; Evoked potential; Infantile spasms; Intramyelinic edema; Magnetic resonance imaging; Refractory epilepsy; Review; Vigabatrin

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PLACEBO; PREDNISOLONE; TETRACOSACTIDE; TIAGABINE; TOPIRAMATE; VIGABATRIN; 4 AMINOBUTYRATE AMINOTRANSFERASE; ANTICONVULSIVE AGENT;

ADD ON THERAPY; ADVERSE DRUG REACTION; ANEMIA; ANTERIOR COMMISSURE; APPETITE; ARTHRALGIA; ARTICLE; BLURRED VISION; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; COMPLEX PARTIAL SEIZURE; CONFUSION; CONSCIOUS SEDATION; CONSTIPATION; CONVULSION; COORDINATION; CORPUS CALLOSUM; COUGHING; DEMYELINATION; DENTATE NUCLEUS; DEPRESSION; DIARRHEA; DIFFUSION TENSOR IMAGING; DIPLOPIA; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EAR INFECTION; EDEMA; EPILEPSY; ERYTHROCYTE; EVOKED RESPONSE; EVOKED SOMATOSENSORY RESPONSE; FATIGUE; FERTILITY; FOOD AND DRUG ADMINISTRATION; GAIT DISORDER; GLOBUS PALLIDUS; HEALTH HAZARD; HEMATOCRIT; HISTOPATHOLOGY; HUMAN; INFANTILE SPASM; INSOMNIA; INTRAMYELINIC EDEMA; IRRITABILITY; LARYNX PAIN; LETHARGY; LONG TERM CARE; LOW DRUG DOSE; MEDICAL RECORD REVIEW; MEDULLA OBLONGATA; MEMORY DISORDER; MENTAL DISEASE; MENTAL FUNCTION; MENTAL PERFORMANCE; MESENCEPHALON; MOOD; MULTICENTER STUDY (TOPIC); NAUSEA; NERVE CONDUCTION; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NEUROSURGERY; NONHUMAN; NOSE CONGESTION; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; OTITIS MEDIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PSYCHOMOTOR PERFORMANCE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SEDATION; SEMANTIC MEMORY; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SORE THROAT; SUICIDAL BEHAVIOR; THALAMUS; TREATMENT DURATION; TREMOR; UNCINATE FASCICULUS; VIRUS INFECTION; VITAMIN D METABOLISM; VOMITING; WEIGHT; WHITE MATTER; ADOLESCENT; ADULT; ANIMAL; BRAIN DISEASE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; FEVER; FOCAL EPILEPSY; HEADACHE; INFANT; MYELIN SHEATH; REVIEW; ULTRASTRUCTURE;

4-AMINOBUTYRATE TRANSAMINASE; ADOLESCENT; ADULT; ANIMALS; ANTICONVULSANTS; BRAIN DISEASES; COGNITION DISORDERS; EDEMA; EPILEPSIES, PARTIAL; EVOKED POTENTIALS, SOMATOSENSORY; FATIGUE; FEVER; HEADACHE; HUMANS; INFANT; IRRITABLE MOOD; MAGNETIC RESONANCE IMAGING; MYELIN SHEATH; NASOPHARYNGITIS; OTITIS MEDIA; RESPIRATORY TRACT INFECTIONS; SLEEP DISORDERS; SPASMS, INFANTILE; TREMOR; VIGABATRIN; VIRUS DISEASES;

EID: 84873048957     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01602.x     Document Type: Article

References (71)

1. Schechter PJ, Tranier Y. Effect of elevated brain GABA concentrations on the actions of bicuculline and picrotoxin in mice. Psychopharmacol 1977;54:145-8.
2. Grove J, Schechter PJ, Tell G et al. Increased gamma-aminobutyric acid (GABA), homocarnosine and beta-alanine in cerebrospinal fluid of patients treated with gamma-vinyl-GABA (4-amino-hex-5-enoic acid). Life Sci 1981;28:2431-9.
3. Ben-Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand 2011;124(Suppl. 192):5-15.
4. Rimmer EM, Richens A. Double-blind study of γ-Vinyl GABA in patients with refractory epilepsy. Lancet 1984;1:189-90.
5. Loiseau P, Hardenberg JP, Pestre M, Guyot M, Schechter PJ, Tell GP. Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia 1986;27:115-20.
6. Tartara A, Manni R, Galimberti CA, Hardenberg J, Orwin J, Perucca E. Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study. Epilepsia 1986;27:717-23.
7. Gram L, Klosterskov P, Dam M. γ-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann Neurol 1985;17:262-6.
8. Browne TR, Mattson RH, Penry JK et al. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology 1987;37:184-9.
9. Tassinari CA, Michelucci R, Ambrosetto G, Salvi F. Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. Arch Neurol 1987;44:907-10.
10. McKee PJW, Blacklaw J, Friel E, Thompson GG, Gillham RA, Brodie MJ. Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients? Epilepsia 1993;34:937-43.
11. Grünewald RA, Thompson PJ, Corcoran R, Corden Z, Jackson GD, Duncan JS. Effects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psychiatr 1994;57:1057-63.
12. French JA, Mosier M, Walker S et al. A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology 1996;46:54-61.
13. Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997;26:389-95.
14. Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 1997;38:1270-4.
15. Dean C, Mosier M, Penry K. Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 1999;40:74-82.
16. Appleton RE, Peters AC, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999;40:1627-33.
17. Elterman RD, Shields WD, Mansfield KA, Nakagawa J, US Infantile Spasms Vigabatrin Study Group. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001;57:1416-21.
18. Lux AL, Edwards SW, Hancock E et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14days: a multicentre, randomised controlled study. Lancet 2004;364:1773-8.
19. Lux AL, Edwards SW, Hancock E et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to 14months: a multicentre randomised trial. Lancet Neurol 2005;4:712-7.
20. Darke K, Edwards SW, Hancock E et al. Developmental and epilepsy outcomes at age 4years in the UK infantile spasms trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child 2010;95:382-6.
21. Elterman RD, Shields WD, Bittman RM, Torri SA, Sagar SM, Collins SD. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J Child Neurol 2010;25:1340-7.
22. Ben-Menachem E, Sander JW. Vigabatrin therapy for refractory complex partial seizures: review of major European trials. Acta Neurol Scand 2011;124(Suppl. 192):16-28.
23. Faught RE. Vigabatrin therapy for refractory complex partial seizures: review of major US trials. Acta Neurol Scand 2011;124(Suppl. 192):29-35.
24. Carmant L. Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing. Acta Neurol Scand 2011;124(Suppl. 192):36-47.
25. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia 2009;50:163-73.
26. Wheless JW, Ramsay RE, Collins SD. Vigabatrin. Neurotherapeutics 2007;4:163-72.
27. Kälviäinen R, Nousiainen I, Mäntyjärvi M et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999;53:922-6.
28. Sergott RC, Westall CA. Primer on visual field testing methods and related algorithms for patients treated with vigabatrin. Acta Neurol Scand 2011;124(Suppl. 192):48-56.
29. Plant GT, Sergott RC. Understanding and interpreting vision safety issues with vigabatrin therapy. Acta Neurol Scand 2011;124(Suppl. 192):57-71.
30. SABRIL® Tablets [prescribing information]. Deerfield, IL: Lundbeck Inc., 2010.
31. Bruni J, Guberman A, Vachon L et al. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. Seizure 2000;9:224-32.
32. Tartara A, Manni R, Galimberti CA et al. Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. Acta Neurol Scand 1992;86:247-51.
33. Pennell PB. Hormonal aspects of epilepsy. Neurol Clin 2009;27:941-65.
34. Calabrò RC, Marino S, Bramanti P. Sexual and reproductive dysfunction associated with antiepileptic drug use in men with epilepsy. Expert Rev Neurother 2011;11:887-95.
35. Erel T, Guralp O. Epilepsy and menopause. Arch Gynecol Obstet 2011;284:749-55.
36. Meier C, Kraenzlin ME. Antiepileptics and bone health. Ther Adv Musculoskelet Dis 2011;3:235-43.
37. SABRIL® Oral Solution [prescribing information]. Deerfield, IL: Lundbeck Inc., 2010.
38. Butler WH, Ford GP, Newberne JW. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol 1987;15:143-8.
39. Gibson JP, Yarrington JT, Loudy DE, Gerbig CG, Hurst GH, Newberne JW. Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1990;18:225-38.
40. Cohen JA, Fisher RS, Brigell MG, Peyster RG, Sze G. The potential for vigabatrin-induced intramyelinic edema in humans. Epilepsia 2000;41:148-57.
41. Yarrington JT, Gibson JP, Dillberger JE et al. Sequential neuropathology of dogs treated with vigabatrin, a GABA-transaminase inhibitor. Toxicol Pathol 1993;21:480-9.
42. Walzer M, Bekersky I, Wanaski S et al. Oral toxicity of vigabatrin in immature rats: characterization of intramyelinic edema [published online ahead of print April 4, 2011]. Neurotoxicology. doi.
43. Arezzo JC, Schroeder CE, Litwak MS, Steward DL. Effects of vigabatrin on evoked potentials in dogs. Br J Clin Pharmacol 1989;27(Suppl 1):53S-60S.
44. Schroeder CE, Gibson JP, Yarrington J, Heydorn WE, Sussman NM, Arezzo JC. Effects of high-dose gamma-vinyl GABA (vigabatrin) administration on visual and somatosensory evoked potentials in dogs. Epilepsia 1992;33(Suppl 5):S13-25.
45. Jackson GD, Williams SR, Weller RO et al. Vigabatrin-induced lesions in the rat brain demonstrated by quantitative magnetic resonance imaging. Epilepsy Res 1994;18:57-66.
46. Weiss KL, Schroeder CE, Kastin SJ et al. MRI monitoring of vigabatrin-induced intramyelinic edema in dogs. Neurology 1994;44:1944-99.
47. Peyster RG, Sussman NM, Hershey BL et al. Use of ex vivo magnetic resonance imaging to detect onset of vigabatrin-induced intramyelinic edema in canine brain. Epilepsia 1995;36:93-100.
48. Preece NE, Houseman J, King MD, Weller RO, Williams SR. Development of vigabatrin-induced lesions in the rat brain studied by magnetic resonance imaging, histology, and immunocytochemistry. Synapse 2004;53:36-43.
49. Cannon DJ, Butler WH, Mumford JP, Lewis PJ. Neuropathologic findings in patients receiving long-term vigabatrin therapy for chronic intractable epilepsy. J Child Neurol 1991;2:S17-24.
50. Pedersen B, Højgaard K, Dam M. Vigabatrin: no microvacuoles in a human brain. Epilepsy Res 1987;1:74-6.
51. Hammond EJ, Ballinger WE Jr, Lu L, Wilder BJ, Uthman BM, Reid SA. Absence of cortical white matter changes in three patients undergoing long-term vigabatrin treatment. Epilepsy Res 1992;12:261-5.
52. Sivenius J, Paljärvi L, Vapalahti M, Nousiainen U, Riekkinen PJ. Vigabatrin (gamma-vinyl-GABA): neuropathologic evaluation in five patients. Epilepsia 1993;34:193-6.
53. Pearl PL, Vezina LG, Saneto RP et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009;50:184-94.
54. Wheless JW, Carmant L, Bebin M et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009;50:195-205.
55. Dracopoulos A, Widaja E, Raybaud C, Westall CA, Snead OC III. Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms. Epilepsia 2010;51:1297-304.
56. Milh M, Villeneuve N, Chapon F et al. Transient brain magnetic resonance imaging hyperintensity in basal ganglia and brain stem of epileptic infants treated with vigabatrin. J Child Neurol 2009;24:305-15.
57. Simao GN, Mahmoodabadi SZ, Snead OC, Go C, Widjaja E. Abnormal axial diffusivity in the deep gray nuclei and dorsal brain stem in infantile spasm treated with vigabatrin. AJNR Am J Neuroradiol 2011;32:199-203.
58. Horton M, Rafay M, Del Bigio MR. Pathological evidence of vacuolar myelinopathy in a child following vigabatrin administration. J Child Neurol 2009;24:1543-6.
59. Iyer RS, Chaturvedi A, Pruthi S, Khanna PC, Ishak GE. Medication neurotoxicity in children [published online ahead of print July 23, 2011]. Pediatr Radiol. doi.
60. Thapa M, Khanna PC. Vigabatrin-associated diffusion MRI abnormalities in tuberous sclerosis. Pediatr Radiol 2010;48(Suppl 1):S153.
61. Trimble MR. Interictal psychoses of epilepsy. Adv Neurol 1991;55:143-52.
62. Trimble MR. Anticonvulsant-induced psychiatric disorders. The role of forced normalisation. Drug Saf 1996;15:159-66.
63. Cockerell OC, Moriarity J, Tromble M, Sander JW, Shovron SD. Acute psychological disorders in patients with epilepsy: a nation-wide study. Epilepsy Res 1996;25:119-31.
64. Dodrill CB, Arnett JL, Sommerville KW, Sussman NM. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life. Epilepsia 1995;36:164-73.
65. Kälviäinen R, Aikiä M, Suaukkonen AM, Mervaala E, Riekkinen PJ Sr. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol 1995;52:989-96.
66. Gillham RA, Blacklaw J, McKee PJW, Brodie MJ. Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. J Neurol Neurosurg Psychiatry 1993;56:1271-5.
67. Mula M, Hesdorffer DC. Suicidal behavior and antiepileptic drugs in epilepsy: analysis of the emerging evidence. Drug Healthc Patient Saf 2011;3:15-20.
68. Hamed SA. Psychiatric symptomatologies and disorders related to epilepsy and antiepileptic medications [published online ahead of print May 28, 2011]. Expert Opin Drug Saf. doi.
69. Sander JW, Hart YM, Trimble MR, Shovron SD. Vigabatrin and psychosis. J Neurol Neurosurg Psychiatry 1991;54:435-9.
70. Levinson DF, Devinsky O. Psychiatric adverse events during vigabatrin therapy. Neurology 1999;53:1503-11.
71. Food and Drug Administration. Statistical review and evaluation. Epileptic drugs and suicidality. May 2008. Available at: Accessed July 20, 2011.